Xtant Medical Reports Second Quarter 2025 Financial Results

Rhea-AI Summary

Xtant Medical (NYSE American: XTNT) reported strong Q2 2025 financial results with revenue growing 18% to $35.4 million. The company achieved significant improvements, including a gross margin of 68.6% and net income of $3.6 million, compared to a net loss in the prior year.

Key developments include the planned sale of non-core assets to Companion Spine for $19.2 million and the launch of two new products: OsteoFactor Pro™ and Trivium™. The company has raised its FY25 revenue guidance to $131-135 million, projecting 11-15% growth. Operating performance showed marked improvement with Adjusted EBITDA of $6.9 million and positive operating cash flow of $1.2 million.

Positive

• Revenue increased 18% year-over-year to $35.4 million
• Significant margin improvement to 68.6% from 62.1% year-over-year
• Achieved net income of $3.6 million versus prior year loss of $3.9 million
• Strategic sale of non-core assets to Companion Spine for $19.2 million
• Raised FY25 revenue guidance to $131-135 million
• Generated positive operating cash flow of $1.2 million
• Improved Adjusted EBITDA to $6.9 million from -$0.6 million year-over-year

Negative

• Operating expenses remain high at $19.7 million despite reduction
• Cash position relatively modest at $7.0 million

Insights

Financial Analyst

Xtant delivered strong Q2 with 18% revenue growth, profitability turnaround, margin expansion, and raised guidance amid strategic refocusing on core biologics.

Xtant Medical's Q2 results demonstrate a remarkable financial turnaround with revenue increasing 18% year-over-year to $35.4 million, significantly outpacing industry growth rates. The company's gross margin expanded substantially from 62.1% to 68.6%, reflecting improved operational efficiency and the positive impact of higher-margin royalty revenues.

The profitability transformation is particularly noteworthy – Xtant swung from a $3.9 million net loss in Q2 2024 to positive net income of $3.6 million, while Adjusted EBITDA improved dramatically from a $0.6 million loss to a $6.9 million gain. This represents a remarkable 1300% improvement in EBITDA performance year-over-year.

Cash flow trends are equally impressive, with operations generating $1.2 million versus consuming $5.1 million in the prior year period – a $6.3 million positive swing that demonstrates strengthening fundamentals. The strategic decision to divest non-core spinal implants and international operations for $19.2 million will further bolster the balance sheet while sharpening focus on higher-margin biologics.

Management's decision to raise full-year revenue guidance to $131-135 million (representing 11-15% growth) signals confidence in sustained momentum. The company's vertical integration across orthobiologic categories provides competitive differentiation, while new product introductions like OsteoFactor Pro and Trivium support the growth trajectory. Notably, the company's cash position improved to $7.0 million from $6.2 million at year-end, demonstrating financial discipline alongside growth execution.

Total Revenue of $35.4 Million Increased 18% Year-over-Year

Delivers Positive Net Income, Adjusted EBITDA and Operating Cash Flow

Raises FY25 Revenue Guidance to $131-$135 Million, Representing Growth of 11%-15% over FY24

BELGRADE, Mont., Aug. 12, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today reported financial and operating results for the second quarter ended June 30, 2025.

Second Quarter 2025 Financial Highlights

• Revenue of $35.4 million, up 18%, compared to the prior year quarter
• Gross margin of 68.6% compared to 62.1% for the prior year quarter
• Net income of $3.6 million compared to a net loss of $3.9 million in the prior year quarter
• Adjusted EBITDA of $6.9 million compared to Adjusted EBITDA loss of $0.6 million in the prior year quarter
• Cash generated from operations of $1.2 million compared to cash used in operations of $5.1 million in the prior year quarter
• Raised FY25 revenue guidance to $131-$135 million, representing growth of 11%-15%, excluding the impact of the pending sale of certain assets to Companion Spine

Recent Business Highlights

• Announced definitive agreements to sell its non-core Coflex® and CoFix® spinal implants and all OUS businesses to Companion Spine for total proceeds of approximately $19.2 million
• Launched OsteoFactor Pro™, a naturally occurring cocktail of allogeneic growth factors engineered and designed to improve bone healing and support surgical success across orthopedic and spine procedures
• Launched Trivium™, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures

Sean Browne, President and CEO of Xtant Medical, stated, "We delivered strong financial and operating results during the second quarter, reflecting steps taken to enhance our focus on our core biologics business while also prudently managing expenses across the organization and driving operating leverage, consistent profitability, and cash flow. Notably, with the recent launch of our next-generation growth factor, OsteoFactor Pro™, we are now the only vertically integrated company to develop and manufacture solutions across all major orthobiologic categories."      

Mr. Browne continued, "Our recently announced agreements to sell certain non-core spinal implant and OUS businesses to Companion Spine represent another step toward the realization of our strategic vision for the company. Once completed, this transaction will allow us to significantly strengthen our balance sheet and further support the ongoing development of our broad pipeline of advanced biologics. I believe our tireless commitment to innovation and quality uniquely positions Xtant to address the needs of surgeons and patients alike while simultaneously creating enduring value for our shareholders."      

Second Quarter 2025 Financial Results

Revenue grew 18% to $35.4 million, compared to $29.9 million for the same quarter in 2024. The increase is due primarily to increased orthobiologics sales and licensing revenue.

Gross margin for the second quarter of 2025 was 68.6%, compared to 62.1% for the same period in 2024. The increase is primarily attributable to the impact of royalty revenue in the current year period, as well as lower product costs and greater scale.

Operating expenses for the second quarter of 2025 totaled $19.7 million, compared to $21.5 million for the second quarter of 2024. The reduction in operating expenses is primarily attributable to reduced compensation and commission expenses, which were partially offset by an increase in professional fees related to sales and marketing. 

Net income totaled $3.6 million, or $0.02 per share on a fully diluted basis, compared to a net loss of $3.9 million, or $(0.03) per share, in the second quarter of 2024.

Non-GAAP adjusted EBITDA for the second quarter of 2025 totaled $6.9 million, compared to an Adjusted EBITDA loss of $569,000 for the same period in 2024. Beginning in the fourth quarter of 2024, phasing of the bargain purchase gain on sell through of inventory acquired as part of the purchase of Surgalign Holdings' hardware and biologics business is no longer included in acquisition-related fair value adjustments in the non-GAAP adjusted EBITDA calculation and prior period calculations as presented herein have been recast to conform to the current presentation and calculation.

The Company defines adjusted EBITDA as net income/loss from operations before depreciation, amortization and interest expense and provision for income tax/benefit, and as further adjusted to add back in or exclude, as applicable, separation-related expenses, non-cash compensation, disposition/acquisition-related expense, acquisition-related fair value adjustments and unrealized foreign currency translation gain or loss. A calculation and reconciliation of adjusted EBITDA to net loss can be found in the attached financial tables.

As of June 30, 2025, the Company had $7.0 million of cash and cash equivalents compared to $6.2 million as of December 31, 2024.

2025 Financial Guidance

Xtant is raising its full-year 2025 revenue guidance to a range of $131 million to $135 million, which represents approximately 11% to 15% growth over the Company's 2024 revenue.  This compares to its prior revenue guidance of $127 million to $131 million. Xtant intends to update its outlook following the completion of the  sale of its non-core Coflex® and CoFix® spinal implants and all OUS businesses to Companion Spine.   

Conference Call

Xtant Medical will host a webcast and conference call to discuss its second quarter 2025 financial and operating results at 8:30 am ET today, August 12, 2025.

To access the webcast, visit Webcast Link: https://www.webcaster4.com/Webcast/Page/3039/52698

To access the conference call, dial 877-545-0523 (US) or 973-528-0016 (International) and reference Participant Access Code 482755.

A replay of the call will be available on the Investor section of the Company's website at www.xtantmedical.com.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Non-GAAP Financial Measures

To supplement the Company's consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP financial measures in this release, including adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this release to the most comparable GAAP measures for the respective periods can be found in tables later in this release. The Company's management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company's operations, period over period. Management uses the non-GAAP measures in this release internally for evaluation of the performance of the business, including the allocation of resources. Investors should consider non-GAAP financial measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," "going forward," "guidance," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's full year 2025 revenue guidance and the anticipated closing of the sale of the Company's Coflex® and CoFix® spinal implants and all OUS businesses to Companion Spine and proceeds therefrom. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the possibility that the sale of the Company's Coflex and CoFix products and international business are not completed or, if completed, that the anticipated benefits of the transactions are not realized when expected or at all; the possibility that the transactions may be more expensive to complete than anticipated; diversion of management's attention from ongoing business operations and opportunities; the occurrence of any event, change or other circumstances that could give rise to the right of the parties to terminate either or both transactions; exposure to potential litigation and adverse tax consequences; the Company's future operating results and financial performance; its ability to increase or maintain revenue; the Company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; risks associated with its acquisitions and the integration of those businesses; anticipated shortages of stem cells which will adversely affect future revenues; the ability to implement successfully its future growth initiatives and risks associated therewith; possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory; the ability to remain competitive; the ability to innovate, develop and introduce new products and the success of those products; the ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets; the effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product liability claims and other litigation to which the Company may be subject; the effect of product recalls and defects; the ability to license certain of the Company's intellectual property on commercially reasonable terms and to maintain any such licenses; the ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others; risks associated with the Company's clinical trials; international risks; the ability to service Company debt, comply with its debt covenants and access additional indebtedness; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent SEC reports, including its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 to be filed with the SEC on August 12, 2025. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.

-- Tables Follow –

 

XTANT MEDICAL HOLDINGS, INC. Condensed Consolidated Balance Sheets (In thousands, except number of shares and par value)
		As of June 30, 2025		As of December 31, 2024
ASSETS
Current Assets:
Cash and cash equivalents		$      6,923		$           6,199
Restricted cash		114		22
Trade accounts receivable, net of allowance for credit losses and doubtful accounts of $1,795 and $1,437, respectively		26,951		20,660
Inventories		40,135		38,634
Prepaid and other current assets		1,466		1,601
Total current assets		75,589		67,116
Property and equipment, net		10,447		10,131
Right-of-use asset, net		2,634		829
Goodwill		7,302		7,302
Intangible assets, net		7,492		8,356
Other assets		15		103
Total Assets		$  103,479		$         93,837
LIABILITIES & STOCKHOLDERS' EQUITY
Current Liabilities:
Accounts payable		$      7,223		$           7,918
Accrued liabilities		10,626		7,771
Current portion of lease liability		693		703
Current portion of finance lease obligations		52		69
Line of credit		12,006		12,120
Total current liabilities		30,600		28,581
Long-term Liabilities:
Lease liability, less current portion		2,015		166
Financing lease obligations, less current portion		30		47
Long-term debt, plus premium and less issuance costs		22,278		22,038
Other liabilities		54		42
Total Liabilities		54,977		50,874
Stockholders' Equity
Preferred stock, $0.000001 par value; 10,000,000 shares authorized; no shares issued and outstanding		-		-
Common stock, $0.000001 par value; 300,000,000 shares authorized; 139,315,722 shares issued and outstanding as of June 30, 2025 and 139,045,664 shares issued and outstanding as of December 31, 2024		-		-
Additional paid-in capital		304,201		302,738
Accumulated other comprehensive income (loss)		152		(316)
Accumulated deficit		(255,851)		(259,459)
Total Stockholders' Equity		48,502		42,963
Total Liabilities & Stockholders' Equity		$  103,479		$         93,837

 

XTANT MEDICAL HOLDINGS, INC. Condensed Consolidated Statements of Operations (Unaudited, in thousands, except number of shares and per share amounts)
		Three Months Ended June 30,			Six Months Ended  June 30,
		2025		2024		2025			2024
Revenue
Product revenue		$30,436		$29,943		$59,720			$57,816
License revenue		4,975		-		8,595			-
Total Revenue		35,411		29,943		68,315			57,816
Cost of Sales		11,127		11,361		23,788			21,932
Gross Profit		24,284		18,582		44,527			35,884
Gross Profit %		68.6 %		62.1 %		65.2 %			62.1 %
Operating Expenses
General and administrative		7,478		7,713		15,011			15,498
Sales and marketing		11,616		13,179		22,820			25,639
Research and development		566		636		1,009			1,163
Total Operating Expenses		19,660		21,528		38,840			42,300
Income (Loss) from Operations		4,624		(2,946)		5,687			(6,416)
Other Expense
Interest expense		(1,004)		(992)		(2,049)			(1,827)
Unrealized foreign currency translation gain		178		118		202			79
Other income (expense)		7		(5)		(2)			7
Total Other Expense		(819)		(879)		(1,849)			(1,741)
Net Income (Loss) from Operations Before Provision for Income Taxes		3,805		(3,825)		3,838			(8,157)
Provision for Income Taxes
Current and Deferred		(255)		(36)		(230)			(104)
Net Income (Loss)		$3,550		$(3,861)		$3,608			$(8,261)
Net Income (Loss) Per Share:
Basic		$    0.03		$ (0.03)		$    0.03			$ (0.06)
Dilutive		$    0.02		$ (0.03)		$   0.02			$ (0.06)
Shares used in the computation:
Basic		139,310,589		130,269,710		139,190,378			130,291,796
Dilutive		148,574,242		130,269,710		148,339,423			130,291,796

 

XTANT MEDICAL HOLDINGS, INC. Condensed Consolidated Statements of Cash Flows (Unaudited, in thousands)
		Six Months Ended June 30,
		2025		2024
Operating activities:
Net income (loss)		$   3,608		$(8,261)
Adjustments to reconcile net income (loss) to net cash provided by  (used in) operating activities:
Depreciation and amortization		2,243		2,003
Gain on sale of fixed assets		(49)		(142)
Non-cash interest		289		218
Stock-based compensation		1,524		2,138
Provision for reserve on accounts receivable		395		178
Provision for excess and obsolete inventory		490		388
Other		46		1
Changes in operating assets and liabilities:
Accounts receivable		(6,873)		(688)
Inventories		(1,349)		(4,130)
Prepaid and other assets		347		(469)
Accounts payable		(880)		(15)
Accrued liabilities		2,763		(2,064)
Net cash provided by (used in) operating activities		2,554		(10,843)
Investing activities:
Purchases of property and equipment		(1,557)		(1,337)
Proceeds from sale of fixed assets		97		183
Net cash used in investing activities		(1,460)		(1,154)
Financing activities:
Payments on financing leases		(34)		(32)
Borrowings on line of credit		51,812		59,565
Repayments on line of credit		(51,925)		(52,288)
Proceeds from issuance of long term debt		-		5,000
Debt issuance costs		(49)		(615)
Payment of taxes from withholding of common stock on   settlement of restricted stock units		(61)		(17)
Net cash (used in) provided by financing activities		(257)		11,613
Effect of exchange rate changes on cash and cash equivalents and restricted cash		(21)		(61)
Net change in cash and cash equivalents and restricted cash		816		(445)
Cash and cash equivalents and restricted cash at beginning of year		6,221		5,923
Cash and cash equivalents and restricted cash at end of year		$ 7,037		$  5,478
Reconciliation of cash and cash equivalents and restricted cash reported in the consolidated balance sheets
Cash and cash equivalents		6,923		5,379
Restricted cash		114		99
Total cash and restricted cash reported in the consolidated balance sheets		$   7,037		$   5,478

 

XTANT MEDICAL HOLDINGS, INC. CALCULATION OF NON-GAAP CONSOLIDATED EBITDA AND ADJUSTED EBITDA  (in thousands)
		Three Months Ended June 30,			Six Months Ended June 30,
		2025	2024			2025	2024
Net Income (Loss)		$         3,550	$   (3,861)			$     3,608	$(8,261)
Depreciation and amortization		1,169	998			2,243	2,003
Interest expense		1,004	992			2,049	1,827
Tax (benefit) expense		255	36			230	104
Non-GAAP EBITDA		5,978	(1,835)			8,130	(4,327)
Non-GAAP EBITDA/Total revenue		16.9 %	-6.1 %			11.9 %	-7.5 %
NON-GAAP ADJUSTED EBITDA CALCULATION
Separation related expenses		(17)	-			23	-
Non-cash compensation		766	1,228			1,524	2,138
Divestiture/acquisition-related expense		295	-			295	338
Acquisition-related fair value adjustments (1)		60	129			171	384
Unrealized foreign currency translation (gain)   loss		(178)	(118)			(202)	(79)
Non-GAAP Adjusted EBITDA		$        6,904	$      (596)			$      9,941	$(1,546)
Non-GAAP Adjusted EBITDA/Total revenue		22.7 %	-2.0 %			16.6 %	-2.7 %

(1) Beginning in the fourth quarter of 2024, phasing of the bargain purchase gain on sell through of inventory acquired as part of the purchase of Surgalign Holdings' hardware and biologics business is no longer included in acquisition-related fair value adjustments in the non-GAAP adjusted EBITDA calculation and prior period calculations as presented herein have been recast to conform to the current presentation and calculation. The related effect on adjusted EBITDA was a reduction of $1.1 million and $2.1 million for the three and six months ended June 30, 2024 to arrive at recast amounts.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-reports-second-quarter-2025-financial-results-302526986.html

SOURCE Xtant Medical Holdings, Inc.

FAQ

What were Xtant Medical's (XTNT) Q2 2025 earnings results?

Xtant Medical reported Q2 2025 revenue of $35.4 million, up 18% year-over-year, with net income of $3.6 million ($0.02 per share) compared to a net loss of $3.9 million in Q2 2024.

How much is Xtant Medical selling its non-core assets for to Companion Spine?

Xtant Medical is selling its Coflex® and CoFix® spinal implants and OUS businesses to Companion Spine for approximately $19.2 million.

What is Xtant Medical's revenue guidance for FY 2025?

Xtant Medical raised its FY25 revenue guidance to $131-135 million, representing growth of 11-15% over FY24.

What new products did Xtant Medical launch in Q2 2025?

Xtant Medical launched two new products: OsteoFactor Pro™, an allogeneic growth factors solution, and Trivium™, a next-generation demineralized bone matrix allograft.

What was Xtant Medical's gross margin in Q2 2025?

Xtant Medical achieved a gross margin of 68.6% in Q2 2025, up from 62.1% in the same period of 2024, primarily due to royalty revenue and lower product costs.